Month: August 2021

Anexinet Continues Their Strategic Expansion Plans By Acquiring Light Networks

Written by Customer Service on August 12, 2021. Posted in Mergers And Acquisitions.

Acquisition Deepens Anexinet’s Customer Experience, Workplace Modernization, and Infrastructure Solutions PHILADELPHIA, Aug. 12, 2021 (GLOBE NEWSWIRE) — Anexinet Corporation, a leading provider of digital business solutions, and a Mill Point Capital LLC portfolio company, today announced it has entered into a definitive agreement to acquire Light Networks. The acquisition will allow Anexinet to leverage its Artificial Intelligence (AI), process automation, and strong digital solutions alongside Light Networks’ Unified Communications as a Service (UCaaS), Contact Center as a Service (CCaaS), and network/telecom solutions to elevate digital interactions for their customers, employees, and partners. “The acquisition of Light Networks, following our acquisition of SereneIT in Atlanta, demonstrates Anexinet’s rapid growth trajectory...

VectivBio Publishes Invitation to the Extraordinary General Meeting

Written by Customer Service on August 12, 2021. Posted in Public Companies.

BASEL, Switzerland, Aug. 12, 2021 (GLOBE NEWSWIRE) — VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions, today published the invitation to the Extraordinary General Meeting, which will be held on Thursday, September 2, 2021, at 2:00 p.m. CEST / 8:00 a.m. EDT at the offices of VectivBio Holding AG at Aeschenvorstadt 36, 4051 Basel, Switzerland. As previously announced, the sole agenda item of the Extraordinary General Meeting is the election of Paul R. Carter and Dr. Murray W. Stewart as new members of the Board of Directors. In view of the ongoing special situation involving the COVID-19 pandemic, and in accordance with Ordinance 3 of the Swiss Federal Council regarding measures...

Arrival Reports Second Quarter 2021 Financial Results

Written by Customer Service on August 12, 2021. Posted in Earnings Releases And Operating Results.

Significant increase in non-binding Orders and LOIs to 59k¹ vehicles Completed redemption of public warrants with gross proceeds of c.$141 million Announced new Indian R&D engineering facility following significant customer demandRockhill Microfactory over 80% and Bicester over 75% of equipment ordered/delivered LUXEMBOURG, Aug. 12, 2021 (GLOBE NEWSWIRE) — Arrival (NASDAQ: ARVL), pioneer of a unique new method of design and production of affordable electric vehicles (EVs) by local Microfactories, today reported financial results for the second quarter ended June 30, 2021. “We are delighted to have announced our current non-binding Orders and LOIs total c.59k¹ vehicles with the most recent addition in India for our Bus platform,” said Denis Sverdlov, CEO and founder of Arrival. “This highlights the tremendous growth we are...

PDS Biotech Provides Business Update and Reports Second Quarter 2021 Financial Results

Written by Customer Service on August 12, 2021. Posted in Earnings Releases And Operating Results.

FLORHAM PARK, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, will discuss its financial results for the quarter ended June 30, 2021 and provide a business update on its conference call today. Recent Business Highlights:Presented interim Phase 2 clinical data for lead product PDS0101, in an oral presentation at the American Society for Clinical Oncology (ASCO) 2021 Annual Meeting. In the National Cancer Institute-led study, tumor reduction was observed in 83% (5 of 6) of advanced HPV16-positive cancer patients who had relapsed or failed treatment with chemotherapy and radiation but had not been treated with checkpoint inhibitor therapy. Tumor...

Novan Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Written by Customer Service on August 12, 2021. Posted in Earnings Releases And Operating Results.

– Positive data across all three of the Company’s priority pipeline development programs, announced in Q2 2021, further validating the potential of its novel, proprietary NITRICIL™ technology – – Preparation underway for the Company’s first New Drug Application filing for lead program, SB206, following the statistically significant topline efficacy results from pivotal Phase 3 trial in patients with molluscum contagiosum – – Ongoing exploration of opportunities for pipeline expansion and clinical development, leveraging internal expertise and strategic partnerships – – Company to host update conference call and webcast today at 8:30 a.m. ET – DURHAM, N.C., Aug. 12, 2021 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the quarter ended June...

Brain Stroke Market Report 2021 | Size, Share, Growth, Trends, Analysis, Revenue, Competitive Landscape, Forecast

Written by Customer Service on August 12, 2021. Posted in Mergers And Acquisitions.

Top Players Covered in the Brain Stroke Market Research Report Are Medtronic, Stryker, Johnson & Johnson Services, Inc., Abbott, Siemens Healthcare Private Limited, GENERAL ELECTRIC COMPANY and other key market players. Pune, India, Aug. 12, 2021 (GLOBE NEWSWIRE) — The global brain stroke market size is projected to make considerable gains owing to the rising number of aging population across the world. Fortune Business Insights™ shares these observations in its report, titled “Brain Stroke Market, 2021-2028”. Over the years, there has been a significant increase in the number of aging population across the world. This has resulted in the prevalence of various diseases such as heart attack, cancer, brain stroke, and others among the aging population. Thus, this is a major reason responsible for the growth of this market. The...

Vistin Pharma ASA: Invitation to Q2 2021 conference call

Written by Customer Service on August 12, 2021. Posted in Public Companies.

Oslo, Norway, 12 August 2021 Vistin Pharma ASA will release its second quarter 2021 results on Thursday 19th of August 2021. Vistin Pharma will host a conference call for all shareholders and interested parties on Thursday 19th of August at 08:30 CET. There will be a Q&A session following the management discussion. The conference call will be held in English. The second quarter conference call will be available via web and audio through the following access points: Telephone conference:Confirmation Code: 7925407International Dial-In: +44 (0) 203 0095709Norway, Oslo: +47 21033922United States, New York: +1 6467871226 Webcast: https://edge.media-server.com/mmc/p/ejs5nvy8*****For further information, please contact: Alexander KarlsenCFO+47 97053621alexander.karlsen@vistin.comAbout Vistin Pharma | www.vistin.com Vistin...

Silence Therapeutics Reports Half-Year 2021 Results

Written by Customer Service on August 12, 2021. Posted in Public Companies.

Silence Therapeutics Reports Half-Year 2021 ResultsFull enrollment achieved for four cohorts of the APOLLO study of SLN360 in healthy individuals living with high levels of lipoprotein(a) Silence to host R&D Day in New York City on October 21, 2021August 12, 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced results for its half-year ended June 30, 2021. Mark Rothera, President and CEO of Silence Therapeutics, commented: “The first half of 2021 was marked by strong execution, highlighted by the first clinical data from our proprietary mRNAi GOLD™ platform that successfully translated results...

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results

Written by Customer Service on August 12, 2021. Posted in Public Companies.

Total of 509 Patients Enrolled in Confirmatory Late-stage Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s DiseaseExceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2/3 AVATAR Clinical Trial in Patients with Rett SyndromeCurrent Cash Position of $157.6 millionWebcast and Conference Call Today at 4:30 p.m. EDTNEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal...

Applied Therapeutics Reports Second Quarter 2021 Financial Results

Written by Customer Service on August 12, 2021. Posted in Public Companies.

NDA submission for AT-007 in Galactosemia expected in Q3 2021; commercial preparations ongoing Ended Q2 2021 with a strong balance sheet with $125.6 million in cash and cash equivalents and short-term investments NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the second quarter ended June 30, 2021. “Our pediatric Galactosemia program advanced significantly in the second quarter,” said Shoshana Shendelman, PhD, CEO, Founder and Chair of the Board of Applied Therapeutics. “We continue to prepare for our NDA submission in the third quarter and our anticipated commercial launch in 2022. We...

Month: August 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals